Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Therapeutics reported positive Phase 1 clinical data for its CD19 T-cell engager CLN-978 in rheumatoid arthritis, including clinical remission in a poly-refractory patient with a DAS28-ESR score dropping from 4.0 to 2.2. Data for its BCMA T-cell engager velinotamig showed complete renal responses and rapid reductions in disease activity scores in two patients with refractory systemic lupus erythematosus.
Key figures
- Drug Name
- CLN-978, velinotamig
- Phase Of Trial
- Phase 1
- Cln978 ra remission
- 1 patient achieved DAS28-ESR remission
- Cln978 molecular weight
- 65 kDa
- Velinotamig sle patients
- 2
- Cln978 ra das28 reduction
- 4.0 to 2.2 at week 4
- Velinotamig sle renal response
- complete renal response in both patients
- Velinotamig sle sledai reduction
- 16 to 0 and 14 to 2 at week 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.